Aplastic Anemia
Article information
J Korean Med Assoc. 2006;49(10):885-896
Publication date (electronic) : 2006 October 31
doi :
https://doi.org/10.5124/jkma.2006.49.10.885
Abstract
Aplastic anemia (AA) is a rare hematopoietic stem-cell disorder that results in pancytopenia and hypocellular bone marrow. The pathophysiology of acquired AA is immune-mediated in most cases. Activated type 1 cytotoxic T cells mediate the destruction of hematopoietic stem cells. The aberrant immune response and deficiencies in hematopoietic cells is now elucidated by molecular studies. In recent days, either stem cell transplant or immunosuppressive drug therapy with better supportive care has greatly improved the outcomes of patients with otherwise fatal disease. Combined immunosuppression with antithymocyte globulins and cyclosporine are effective in restoring blood counts in the majority of patients, but relapse and clonal evolution remain problematic. Allogeneic stem cell transplantation from matched sibling donors is curative in the great majority of young patients with severe AA. However, the results in patients who are older or lack family donors have room for improvement. Recent transplant results from alternative donors using a variety of conditioning regimens to enhance engraftment have been promising, especially in certain pediatric series.
References
1. Jeong DC, Kang IJ, Koo HH, Kook H, Kim SY, Kim SK, et al. Epidemiology and clinical outcome in children with aplastic anemia in Korea: Retrospective study. Korean J Pediatr Hematol-Oncol 2004. 11137–152.
2. Young NS. In : Young NS, Gerson SL, High K, eds. Acquired aplastic anemia. Clinical Hematology 2006. Philadelphia: Elsevier; 136–157.
3. Sutton JF, Stacey M, Kearns WG, Rieg TS, Young NS, Liu JM. Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes. Pediatr Blood Cancer 2004. 42122–126.
4. Lu J, Basu A, Melenhorst J, Young NS, Brown KE. Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood 2004. 1034588–4593.
5. Maciejewski JP, Risitano A, Kook H, Zeng W, Chen G, Young NS. Immune pathophysiology of aplastic anemia. Int J Hematol 2002. 76Suppl 1. 207–214.
6. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001. 291270–1277.
7. Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol 2003. 373–14.
8. Kook H. Aplastic Anemia: Its Immune Pathophysiology. J Korean Pediatr Soc 2002. 45948–954.
9. Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS. Interferon-γ-induced gene expression in CD34 cells: Identification of pathologic cytokine-specific signature profiles. Blood 2006. 107167–175.
10. Kook H, Risitano AM, Zeng W, Wlodarski M, Lottemann C, Nakamura R, et al. Changes in T-cell receptor Vβ repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood 2002. 993668–3675.
11. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In vivo dominant immune responses in aplastic anemia. Molecular tracking of putative pathogenic T cell clones by TCR β-CDR3 sequencing. Lancet 2004. 364355–364.
12. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Maciejewski JP. Molecular strategies for detection and quantitation of clonal cytotoxic T cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006. 108Epub ahead of print.
13. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006. 108Epub ahead of print.
14. Lee JJ, Kook H, Chung IJ, Na JA, Park MR, Hwang TJ, et al. Telomere length changes in patients with aplastic anaemia. Br J Haematol 2001. 1121025–1030.
15. Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O'Connor KC, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003. 1024567–4575.
16. Young NS. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep 2005. 4103–109.
17. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002. 100786–790.
18. Marsh JC, Ball SE, Darbyshire P, Gordon-Smith EC, Keidan AJ, Martin A, et al. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003. 123782–801.
19. Kook H. Aplastic Anemia. Korean J Pediatr 2004. 47Suppl 2. S242–S256.
20. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003. 1011236–1242.
21. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000. 951931–1934.
22. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003. 2891130–1135.
23. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000. 962049–2054.
24. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006. 133606–611.
25. Brodsky RA, Chen A, Dorr DM, Brodsky I, Jones RJ. High dose cyclophosphamide (CY) for severe aplastic anemia (SAA): safely and long-term follow-up [abstract]. Blood 2005. 106Suppl 1. 41a–42a.
26. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol 1999. 107330–334.
27. Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood 2003. 1023584–3586.
28. Passweg JR, Perez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006. 37641–649.
29. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000. 961690–1697.
30. Kim HJ, Park CY, Park YH, Kim YJ, Kim DW, Min WS, et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant 2003. 3179–86.
31. Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 2005. 130747–751.
32. Srinivasan R, Takahashi Y, McCoy JP, Espinoza-Delgado I, Dorrance C, Igarashi T, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol 2006. 133305–314.
33. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000. 3730–42.
34. Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002. 100799–803.
35. Deeg HJ, O'donnell M, Tolar J, Agarwal R, Harris RE, Feig S, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006. 1081485–1491.
36. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005. 36947–950.
37. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998. 3391565–1577.
38. Kook H, Baek HJ, Hwang TJ, Koo HH, Yoo KH, Sung KW, et al. Unrelated donor umbilical cord blood transplantation in children with acquired aplastic anemia. Korean experience of 12 cases. Blood 2006. submitted.
Article information Continued
Copyright © 2006 Korean Medical Association
